Global Bacterial Vaginosis Drugs Market 2017-2021

  • ID: 4395236
  • Report
  • Region: Global
  • 71 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Bayer
  • Cardinal Health
  • Mylan
  • Novartis
  • MORE
About Bacterial Vaginosis Drugs

BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria.

The analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Bacterial Vaginosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer
  • Pfizer
  • Sanofi
  • Starpharma Holdings
Other prominent vendors
  • Allergan
  • AstraZeneca
  • Cardinal Health
  • Mylan
  • Novartis
  • Sun Pharmaceutical Industries
  • Symbiomix Therapeutics
  • Teva Pharmaceutical Industries
Market drivers
  • Unmet demand in BV treatment market
  • For a full, detailed list, view the full report
Market challenges
  • Development of resistance against antibiotics
  • For a full, detailed list, view the full report
Market trends
  • Growing awareness about controlled use of antibiotics
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Bayer
  • Cardinal Health
  • Mylan
  • Novartis
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline analysis

PART 07: Market segmentation by ROA
  • Oral
  • Topical
PART 08: Geographical segmentation
  • BV drugs market in Americas
  • BV drugs market in EMEA
  • BV drugs market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Growing awareness about controlled use of antibiotics
  • Rising popularity of topical drugs and other treatment options such as probiotic drugs
PART 12: Vendor landscape

PART 13: Key vendor analysis
  • Bayer
  • Pfizer
  • Sanofi
  • Starpharma Holdings
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Risk factors for BV
Exhibit 02: Symptoms, diagnosis, and treatment of BV
Exhibit 03: Global BV drugs market snapshot
Exhibit 04: Global BV drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global BV drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline molecules by vendors
Exhibit 08: Global BV drugs market: Key trials
Exhibit 09: Global BV drugs market by ROA 2016
Exhibit 10: Global BV drugs market by ROA 2016 and 2021
Exhibit 11: Basis for the choice of routes
Exhibit 12: Advantages and disadvantages of oral route of drug administration
Exhibit 13: Global BV oral drugs market 2016-2021 ($ millions)
Exhibit 14: Advantages and disadvantages of topical drugs
Exhibit 15: Global BV topical drugs market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global BV drugs market by geography 2016 and 2021
Exhibit 17: Global BV drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: BV drugs market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: BV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 22: Prevalence rate of BV in Europe
Exhibit 23: Market scenario in APAC
Exhibit 24: BV drugs market in APAC 2016-2021 ($ millions)
Exhibit 25: Complications associated with BV
Exhibit 26: Pregnancy complications due to BV
Exhibit 27: Symptoms of PID
Exhibit 28: Sociocultural factors preventing females from quality health services
Exhibit 29: Women health programs
Exhibit 30: Resistance for clindamycin
Exhibit 31: Major causes of antibiotic resistance
Exhibit 32: Competitive structure analysis of global BV drugs market 2016
Exhibit 33: Bayer: Key highlights
Exhibit 34: Bayer: Strength assessment
Exhibit 35: Bayer: Strategy assessment
Exhibit 36: Bayer: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Exhibit 41: Key highlights
Exhibit 42: Sanofi: Strength assessment
Exhibit 43: Sanofi: Strategy assessment
Exhibit 44: Sanofi: Opportunity assessment
Exhibit 45: Starpharma: Key highlights
Exhibit 46: Starpharma: Strength assessment
Exhibit 47: Starpharma: Strategy assessment
Exhibit 48: Starpharma: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Allergan
  • AstraZeneca
  • Bayer
  • Cardinal Health
  • Mylan
  • Novartis
  • MORE
New Report Released: - Global Bacterial Vaginosis Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global bacterial vaginosis drugs market: Bayer, Pfizer, Sanofi, and Starpharma Holdings.

Other Prominent Vendors in the market are: Allergan, AstraZeneca, Cardinal Health, Mylan, Novartis, Sun Pharmaceutical Industries, Symbiomix Therapeutics, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend in the market is growing awareness about controlled use of antibiotics. Antibiotic resistance is one of the major problems being faced by the medical world today. It is a condition wherein an microorganism changes itself and remains no longer sensitive to that particular antibiotic. Thus, the antibiotic will no longer be capable of killing or inhibiting the growth of bacteria.”

According to the report, one driver in the market is unmet demand in BV treatment market. Unmet demand in the treatment of BV has created great opportunity for the market players. There is huge unmet need in the treatment of BV, especially the recurrent form of the disease. BV is the most common vaginal infection in the women of child bearing age group. Despite being highly prevalent in nature, little has been done in the field. When left untreated, it may lead to severe infections, especially in the case of pregnant women such as preterm births.

Further, the report states that one challenge in the market is development of resistance against antibiotics. The development of multidrug-resistant microbes is one of the major threats to the human health. The microbe changes itself to protect against the antimicrobial agent used and thereby develops resistance to the drug. This develops largely due to the irrational use of drugs. Incorrect prescription of the drugs by physicians or incorrect dosing or course taken by patients leads to the development of resistant drugs. This occurs because of the increased accumulation of drugs in the body. The commonly used antibiotic drugs thus become ineffective against microbes, leading to aggravation of disease in the body.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Bayer
  • Pfizer
  • Sanofi
  • Starpharma Holdings
  • Allergan
  • AstraZeneca
  • Cardinal Health
  • Mylan
  • Novartis
  • Sun Pharmaceutical Industries
  • Symbiomix Therapeutics
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll